Self-monitoring of blood glucose in noninsulin-treated patients with type 2 diabetes: a never ending story?

Recommendations for self-monitoring of blood glucose (SMBG) in the global guidelines for the treatment of patients with type 2 diabetes of the International Diabetes Federation (IDF) summarize our current knowledge and evidence from studies.1 In standard care, the global IDF guidelines recommend SMBG for all newly diagnosed people with type 2 diabetes. In both standard and comprehensive care, the use of SMBG is advised for people with type 2 diabetes on insulin and oral agents.1 Use of SMBG should be considered in the standard care of people with diabetes using oral agents to provide information on hyoglycemia and glucose variability. The guidelines emphasize that SMBG is an integral part of self-management.